drugset / Trial / NCT05062317
ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.
Timeline
- Start
- 2022-04-26
- Primary completion
- 2027-02-28
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | Oxaliplatin | Small molecule | — | Oral |
| Subject | fluorouracil | Small molecule | — | Intravenous |
| Background | Capecitabine | Small molecule | — | Intravenous |
| Background | Leucovorin | Small molecule | — | Oral |